PLEASANTON, Calif.,
May 18 /PRNewswire-FirstCall/ --
Thoratec Corporation (Nasdaq: THOR), a world leader in device-based
mechanical circulatory support therapies to save, support and
restore failing hearts, said today that the Federal Trade
Commission has granted early termination of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, for the previously announced sale of International
Technidyne Corporation (ITC) to Danaher Corporation (NYSE: DHR).
The closing of the transaction remains subject to certain
other customary conditions to closing as well as approval from the
Austrian regulatory authorities. Thoratec continues to expect
that the transaction will close during the second quarter of
2010.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's product lines include
the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS
(Left Ventricular Assist System) with more than 15,000 devices
implanted in patients suffering from heart failure. Thoratec is
headquartered in Pleasanton,
California. For more information, visit the company's web
site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and IVAD is a
trademark of Thoratec Corporation. CentriMag is a registered
trademark of Levitronix, LLC.
Many of the preceding paragraphs, particularly but not
exclusively those addressing timelines for regulatory
approvals, contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements can be identified
by the words, "believes," "views," "expects," "plans," "hopes,"
"could," "will," and other similar words. Actual results, events or
performance could differ materially from these forward-looking
statements based on a variety of factors, many of which are beyond
Thoratec's control. Therefore, readers are cautioned not to put
undue reliance on these statements. Investors are cautioned that
all such statements involve risks and uncertainties, including
risks related to merger, acquisition or divestiture activities,
regulatory approvals, the results of enrollment in and timing of
clinical trials, and the effects of FDA regulatory requirements.
Forward-looking statements contained in this press release should
be considered in light of these factors and those factors discussed
from time to time in Thoratec's public reports filed with the
Securities and Exchange Commission, such as those discussed under
the heading, "Risk Factors," in Thoratec's most recent annual
report on Form 10-K, and as may be updated in subsequent SEC
filings. These forward-looking statements speak only as of the date
hereof. Thoratec undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated
events.
SOURCE Thoratec Corporation